Management of HIV and hepatitis virus coinfection

Bibliography

• Lee W. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
   PubMed Web of Science ®Google Scholar
• Thio C, Seaberg E, Skolasky R, HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002;360:1921-6
   PubMed Web of Science ®Google Scholar
• Zhou J, Dore GJ, Zhang F, Hepatitis B and C virus coinfection in the TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-8
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Mocroft A, Soriano V, Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002
   PubMed Web of Science ®Google Scholar
• Krogsgaard K, Lindhart B, Nielsen J, The influence of HTLV III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 1987;7:37-41
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Donovan B, Nightingale B. The effects of concurrent HIV infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82
   PubMed Web of Science ®Google Scholar
• Colin J, Cazals-Hatem D, Loriot A, Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Di Martino V, Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8
   PubMed Web of Science ®Google Scholar
• Thio CL, Seaberg EC, Skolasky R Jr, HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006;44:S28-34
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Moller N, Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcia-Samaniego J, Valencia E, Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4
   PubMed Web of Science ®Google Scholar
• Bica I, McGovern B, Dhar R, Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-7
   PubMed Web of Science ®Google Scholar
• Puoti M, Spinetti A, Ghezzi A, Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-7
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poiree M, Pradier C, Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-9
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Pialoux G, Bernard N, Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-8
   PubMed Web of Science ®Google Scholar
• Hoffmann CJ, Seaberg EC, Young S, Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009;23:1881-9
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human services. 1st December 2009. p. 1-161. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 14th April 2010]
   Google Scholar
• European AIDS Clinical Society. Guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults (version 5). Available from: http://www.europeanaidsclinicalsociety.org/guidelinespdf/3_Chronic_Hepatitis_B_&_C.pdf. [Accessed 14th April 2010]
   Google Scholar
• Soriano V, Puoti M, Peters M, Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008;22:1399-410
   PubMed Web of Science ®Google Scholar
• Bessesen M, Ives D, Condreay L, Chronic active hepatitis B exacerbations in human immunodeficiency virus–infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5
   PubMed Web of Science ®Google Scholar
• Manegold C, Hannoun C, Wywiol A, Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-8
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Hepatology 2009;50:1-36
   PubMedGoogle Scholar
• Liaw YF, Sheen IS, Chen TJ, Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627-31
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Desrochers M, Infante-Rivard C, A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-5
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007;21(6):771-4
   Google Scholar
• Iloeje UH, Yang HI, Su J, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Di Martino V, Lunel F, Cadranel J, Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996;3:253-60
   Google Scholar
• Di Martino V, Thevenot T, Boyer N, Serum alanine transaminase level is a good predictor of response to interferon therapy for chronic hepatitis B in HIV-infected patients. Hepatology 2000;31:1030-1
   Google Scholar
• Di Martino V, Thevenot T, Colin J, Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Buggisch P, Lutgehetmann M, Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006;11(5):647-52
   Google Scholar
• Johnson RM, Ristig MB, Overton ET, Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007;8:173-81
   PubMed Web of Science ®Google Scholar
• Weltman M, Brotodiharjo A, Crewe E, Co-infection with chronic hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45
   PubMed Web of Science ®Google Scholar
• Dore J, Cooper D, Barret C, Dual efficacy of lamivudine treatment of human immunodeficiency virus–hepatitis B coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-13
   PubMed Web of Science ®Google Scholar
• Hoff J, Bani-Sadr F, Gassin M, Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti–human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-9
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999;30:1302-6
   PubMed Web of Science ®Google Scholar
• Thibault V, Benhamou Y, Seguret C, Hepatitis B virus mutations associated with resistance to lamivudine in patients co-infected with HBV and HIV. J Clin Microbiol 1999;37:3013-6
   PubMed Web of Science ®Google Scholar
• Pillay D, Cane P, Ratcliffe D, Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS 2000;14:1111-6
   Google Scholar
• Dienstag J, Goldin R, Heathcote E, Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Puoti M, Cozzi-Lepri A, Arici C, Impact of lamivudine on the risk of liver-related death in 2,041 HbsAg- and HIV-positive individuals: results from an intercohort analysis. Antivir Ther 2006;11:567-74
   PubMed Web of Science ®Google Scholar
• Rey D, Fritsch S, Schmitt C, Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in HIV co-infected patients. Gastroenterol Clin Biol 2000;24:125-7
   Google Scholar
• Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain is a cause of liver failure in an HIV-infected patient. Gastroenterology 2001;121:1027-8
   PubMed Web of Science ®Google Scholar
• Proia L, Ngui S, Kaur S, Reactivation of hepatitis B in patients with HIV infection treated with combination antiretroviral therapy. Am J Med 2000;108:249-51
   Google Scholar
• Neau D, Schvoerer E, Robert D, Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a HIV-infected patient. J Infect 2000;41:192-4
   PubMed Web of Science ®Google Scholar
• Peters MG, Andersen J, Lynch P, Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-6
   PubMed Web of Science ®Google Scholar
• Hadziyannis S, Tassopoulos N, Heathcote E, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 Years. Gastroenterology 2006;131(6):1743-51
   Google Scholar
• Marcellin P, Chang TT, Lim SG, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48(3):750-8
   Google Scholar
• Benhamou Y, Bochet M, Thibault V, Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23
   PubMed Web of Science ®Google Scholar
• Pessoa MG, Gazzard B, Huang AK, Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-87
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Levine SM, Rose RE, Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew Yoon S, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-10
   Google Scholar
• Sasadeusz J, Audsley JA, Mijch A, The anti-HIV activity of entecavir: a multicenter evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008;22:947-55
   PubMed Web of Science ®Google Scholar
• McMahon MA, Jilek BL, Brennan TP, The HBV drug entecavir–effects on HIV-1 replication and resistance. N Engl J Med 2007;356(25):2614-21
   Google Scholar
• Lai CL, Gane E, Liaw YF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576-88
   Google Scholar
• Liaw YF, Gane E, Leung N, 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136(2):486-95
   PubMed Web of Science ®Google Scholar
• Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009;23:546-7
   PubMed Web of Science ®Google Scholar
• Lin K, Karwowska S, Lam E, Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. J Antimicrob Agents Chemother 2010;54:2670-3
   Google Scholar
• Ying C, De Clercq E, Nicholson W, Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-5
   PubMed Web of Science ®Google Scholar
• Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-8
   PubMed Web of Science ®Google Scholar
• Nunez M, Perez-Olmeda M, Diaz B, Activity of tenofovir on hepatitis B virus replication in HIV–co-infected patients failing or partially responding to lamivudine. AIDS 2002;16:2352-4
   PubMed Web of Science ®Google Scholar
• Ristig M, Crippin J, Aberg J, Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus–coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-7
   PubMed Web of Science ®Google Scholar
• Nelson M, Portsmouth S, Stebbing J, An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-10
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-8
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Fleury H, Trimoulet P, Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006;43(3):548-55
   Google Scholar
• Dore GJ, Cooper DA, Pozniak AL, Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and - experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189(7):1185-92
   Google Scholar
• Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2(3):266-72
   Google Scholar
• Van Bommel F, Wunsche T, Mauss S, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5
   PubMed Web of Science ®Google Scholar
• Snow-Lampart A, Chappell BJ, Curtis M, Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Hepatology 2008;48(Suppl):745A
   Google Scholar
• Verhelts D, Monge M, Meynard JL, Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3
   Google Scholar
• Izzedine H, Isnard-Bagnis C, Hulot JS, Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004;18:1074-6
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8
   PubMed Web of Science ®Google Scholar
• Lim SG, Ng TM, Kung N, A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166(1):49-56
   Google Scholar
• Papatheodoridis G, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-28
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Lai CL, Liaw YF, Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94
   PubMed Web of Science ®Google Scholar
• Degertekin B, Lok AS. Indications for treatment in Hepatitis B. Hepatology 2009;49(5 Suppl):S129-37
   Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009;23(15):1971-5
   Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42(2):283-90
   PubMed Web of Science ®Google Scholar
• Kearney BP, Mathias A, Mittan A, Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006;43(3):278-83
   Google Scholar
• Kiser JJ, Carten ML, Aquilante CL, The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83(2):265-72
   Google Scholar
• Goicoechea M, Liu S, Best B, Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197(1):102-8
   PubMed Web of Science ®Google Scholar
• Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S122-8
   Google Scholar
• Peters MG, Hann H, Martin P, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126(1):91-101
   Google Scholar
• Matthews GV, Avihingsanon A, lewin SR, A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008;48:1062-9
   PubMed Web of Science ®Google Scholar
• van Bommel F, de Man RA, Wedemeyer H. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1355-74
   Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7
   PubMed Web of Science ®Google Scholar
• Lissen E, Clumeck N, Sola R, Histological response to pegIFNalpha-2a (40KD) plus ribavirinin HIV-hepatitis C virus co-infection. AIDS 2006;20:2175-81
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007;46:613-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007;38:32-8
   PubMed Web of Science ®Google Scholar
• Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23:1000-8
   PubMed Web of Science ®Google Scholar
• Shores NJ, Maida I, Soriano V, Nunez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol 2008;49:323-8
   Google Scholar
• Soriano V, Puoti M, Sulkowski M, Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89
   PubMed Web of Science ®Google Scholar
• Castera L, Vergniol J, Foucher J, Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50
   PubMed Web of Science ®Google Scholar
• Ziol M, Handra-Luca A, Kettaneh A, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48-54
   Google Scholar
• Sterling RK, Lissen E, Clumeck N. Development of a simple noninvasive index to predict significantfibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25
   PubMed Web of Science ®Google Scholar
• Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005;6:375-8
   PubMed Web of Science ®Google Scholar
• Kelleher TB, Mehta SH, Bhaskar R, Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84
   PubMed Web of Science ®Google Scholar
• Myers RP, Benhamou Y, Imbert-Bismut F, Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17:721-5
   PubMed Web of Science ®Google Scholar
• Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47:94-101
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Torbenson MS, Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21:2209-16
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
   PubMed Web of Science ®Google Scholar
• Nunez M, Ocampo A, Aguirrebengoa K, Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-9
   Google Scholar
• Mauss S, Valenti W, DePamphilis J, Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36
   Google Scholar
• Crespo M, Sauleda S, Esteban JI, Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-38
   PubMed Web of Science ®Google Scholar
• Perez-Olmeda M, Nunez M, Romero M, Pegylated IFN-alpha2b plus ribavirin as therapy forchronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-8
   PubMed Web of Science ®Google Scholar
• Cargnel A, Angeli E, Mainini A, Open, randomized, multicentreitalian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfectedpatients on HAART. Antivir Ther 2005;10:309-17
   PubMed Web of Science ®Google Scholar
• Santin M, Shaw E, Garcia MJ, Efficacy and safety of pegylated interferon-alpha2b plusribavirin for the treatment of chronic hepatitis C in HIV infected patients. AIDS Res Hum Retroviruses 2006;22:315-20
   PubMed Web of Science ®Google Scholar
• Voigt E, Schulz C, Klausen G, Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV coinfected patients. J Infect 2006;53:36-42
   PubMed Web of Science ®Google Scholar
• Nunez M, Miralles C, Berdun MA, Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-82
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31
   PubMed Web of Science ®Google Scholar
• Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am J Gastroenterol 2009;104:2335-41
   Google Scholar
• Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007;14:239-48
   Google Scholar
• Hadziyannis SJ, Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol 2000;14:277-91
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Rendon AL, Nunez M, Romero M, Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005;39(4):401-5
   Google Scholar
• Mangia A, Santoro R, Minerva N, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S, Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Diago M, Escartin P, Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60
   PubMed Web of Science ®Google Scholar
• Jensen DM, Morgan TR, Marcellin P, Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60
   PubMed Web of Science ®Google Scholar
• Crespo M, Esteban JI, Ribera E, Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007;21:477-81
   Google Scholar
• Hopkins S, Lambourne J, Farrell G, Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006;7:248-54
   PubMed Web of Science ®Google Scholar
• Van den Eynde E, Crespo M, Esteban JI, Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009;48:1152-9
   PubMed Web of Science ®Google Scholar
• Pariante CM, Orru MG, Baita A, Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354(9173):131-2
   Google Scholar
• Musselman DL, Lawson DH, Gumnick JF, Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344(13):961-6
   Google Scholar
• Schaefer M, Schmidt F, Folwaczny C, Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-51
   Google Scholar
• Schaefer M, Schwaiger M, Garkisch AS, Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42(6):793-8
   Google Scholar
• Cai W, Khaoustov VI, Xie Q, Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005;42:880-7
   PubMed Web of Science ®Google Scholar
• Vogt MW, Hartshorn KL, Furman PA, Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9
   PubMed Web of Science ®Google Scholar
• Nunez M, Ocampo A, Aguirrebengoa K, Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-9
   Google Scholar
• Vispo E, Barreiro P, Pineda JA, Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-37
   PubMed Web of Science ®Google Scholar
• Mira JA, Lopez-Cortes LF, Barreiro P, Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analoguebackbone. J Antimicrob Chemother 2008;62:1365-73
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Denoeud L, Morand P, Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination:does abacavir play a role? J Acquir Immune Defic Syndr 2007;45:123-5
   PubMed Web of Science ®Google Scholar
• Laufer N, Laguno M, Perez I, Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008;13:953-7
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J Viral Hepat 2009;16:833-43
   Google Scholar
• Myers RP, Benhamou Y, Bochet M, Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus–co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004;18:75-9
   PubMed Web of Science ®Google Scholar
• Crespo M, Mira A, Pineda J, Efficacy of peguilated interferon ans ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon based regimen. J Antimicrob Chemother 2008;62:793-6
   PubMed Web of Science ®Google Scholar
• Bruix J, Poynard T, Colombo M, PegIntron maintenance therapy in cirrhotic (Metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final Results of the EPIC3 Cirrhosis Maintenance Trial. 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, 22 – 26 April 2009
   Google Scholar
• Di Bisceglie AM, Shiffman ML, Everson GT, Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41
   PubMed Web of Science ®Google Scholar
• Sherman K, Andersen J, Butt A, Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV-co-infected patients: early viral response and effect on fibrosis in treated and control subjects [abstract 59]. 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, 3 – 6 February 2008
   Google Scholar
• Urbanus AT, van de Laar TJ, Stolte IG, Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009;23:F1-7
   PubMed Web of Science ®Google Scholar
• Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010;65:4-9
   Google Scholar
• Dionne-Odom J, Osborn MK, Radziewicz H, Acute hepatitis C and HIV coinfection. Lancet Infect Dis 2009;9:775-83
   Google Scholar
• Dore GJ, Hellard M, Matthews GV, Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138:123-35
   Google Scholar
• Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009;18:709-25
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir A, PROVE 3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy [abstract 66]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 – November 1 2009
   Google Scholar
• Marcellin P, Forns X, Goeser T, Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208 [abstract 194]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 – November 1 2009
   Google Scholar
• Kwo PY, Lawitz E, McCone J, High Sustained Virologic Response (SVR) in Genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with Boceprevir (Boc) combination therapy [abstract 62]. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, October 30 – November 1 2009
   Google Scholar
• Sherman KE, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: Conference Proceedings. Hepatology 2010;51:1046-54
   Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
   PubMed Web of Science ®Google Scholar
• Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-85
   PubMed Web of Science ®Google Scholar
• Kempf D, Klein C, Chen H-J, Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-7
   PubMedGoogle Scholar
• He Y, King MS, Kempf DJ, Relative replication capacity and selective advantage profiles of protease inhibitorresistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 2008;52:1101-10
   PubMed Web of Science ®Google Scholar
• Gaudieri S, Rauch A, Pfafferott K, Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009;49:1069-82
   PubMed Web of Science ®Google Scholar
• Lopez-Labrador FX, Moya A, Gonzales-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 2008;13:481-94
   PubMed Web of Science ®Google Scholar
• Morsica G, Bagaglio S, Uberti-Foppa C, Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009;51:106-8
   Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Nattermann J, Vogel M, Baumgarten A, Genetic variation in IL28B and treatment-induced clearance of HCV in HCV/HIV co-infected patients [abstract 164 LB]. 17th Conference on Retrovirus and Opportunistic Infections (CROI). San Francisco, 16 – 19 February 2010
   Google Scholar
• Rallon N, Naggie S, Benito J, Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9
   PubMed Web of Science ®Google Scholar
• Veronese L, Rautaureau J, Sadler BM, Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000;44:821-6
   PubMed Web of Science ®Google Scholar
• Meynard JL, Lacombe K, Poirier JM, Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. Antimicrob Chemother 2009;63:579-84
   Google Scholar
• Miro JM, Aguero F, Laguno M, Liver transplantation in HIV/hepatitis coinfection. J HIV Ther 2007;12:24-35
   Google Scholar
• de Vera ME, Dvorchik I, Tom K, Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006;6:2983-93
   PubMed Web of Science ®Google Scholar
• Di Benedetto F, Di Sandro S, De Ruvo N, Human immunodeficiency virus and liver transplantation: our point of view. Transplant Proc 2008;40:1965-71
   PubMed Web of Science ®Google Scholar
• Duclos-Vallee JC, Feray C, Sebagh M, Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407-17
   PubMed Web of Science ®Google Scholar
• Testillano M, Fernandez JR, Suarez MJ, Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. Transplant Proc 2009;41:1041-3
   Google Scholar
• Schreibman I, Gaynor JJ, Jayaweera D, Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007;84:697-705
   Google Scholar
• Roland ME, Barin B, Carlson L, HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355-65
   PubMed Web of Science ®Google Scholar
• Duclos-Vallee JC, Feray C, Sebagh M, Liver transplantation in HIV-HCV and HIVHBV coinfected patients: a large experience in a single centre. J Hepatol 2006;44:S8
   Google Scholar
• Norris S, Taylor C, Muiesan P, Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004;10:1271-8
   PubMedGoogle Scholar
• Fung J, Eghtesad B, Patel-Tom K, Liver transplantation in patients with HIV infection. Liver Transpl 2004;10:S39-53
   Google Scholar
• Tateo M, Roque-Afonso AM, Antonini TM, Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009;23(9):1069-76
   Google Scholar
• Coffin CS, Stock PG, Dove LM, Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010;16:56-63
   Google Scholar
• Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004;18(15):2039-45
   Google Scholar
• Puoti M, Cozzi-Lepri A, Ancarani F, The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? Antivir Ther 2004;9(5):811-7
   Google Scholar
• Lacombe K, Boyd A, Guechot J, The long-term use of tenofovir in HIV/HBV co-infection induces a marked decrease in liver fibrosis [abstract 815]. 16th Conference on Retrovirus and Opportunistic Infections, Montreal, Canada, 8 – 11th February 2009
   Google Scholar
• Lee T, Nunez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009;10:153-9
   PubMed Web of Science ®Google Scholar
• Konopnicki D, Mocroft A, de Wit S, Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Bedossa P, Rosenthal E, Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? J Acquir Immune Defic Syndr 2009;50:234-6
   Google Scholar
• Mehta SH, Thomas DL, Torbenson M, The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005;41:123-31
   PubMed Web of Science ®Google Scholar
• Qurishi N, Kreuzberg C, Luchters G, Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13
   PubMed Web of Science ®Google Scholar
• Marine-Barjoan E, Saint-Paul MC, Pradier C, Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004;18:2163-70
   PubMed Web of Science ®Google Scholar
• Brau N, Salvatore M, Rios-Bedoya CF, Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55
   PubMed Web of Science ®Google Scholar
• Beltz A, High K, Nunez M. Effect of HIV on levels of serum markers of liver inflammation and fibrosis in hepatitis C virus co-infection [abstract 1343]. 60th Annual Meeting of the American Association for the Study of Liver Disease. Boston, MA, October 30th – November 3rd 2009
   Google Scholar